PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26447219-8	2016	In parallel, mesangial cell activation was observed by increased alpha-smooth muscle actin and transforming growth factor-beta, which was blocked by the CYP2E1 inhibitor diallyl sulphide both in vivo and in vitro.	allyl sulfide	170-186	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	153-159	
19875617-1	2009	In order to probe into the effects of garlic oil (GO) on the hepatic CYP2E1, CYP1A2 and CYP3A, male Kun-Ming mice were treated with GO (100 mg/kg body weight) or corn oil for 1 day or consecutive 60 days, respectively, and then the protein expressions and the activities of the enzymes were examined.	allyl sulfide	50-52	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	69-75	
23749193-3	2013	In this study, we co-administered mice with a nitrile and, to reduce their lethal effects, a selective CYP2E1 inhibitor: diallylsulfide (DAS) or trans-1,2-dichloroethylene (TDCE).	allyl sulfide	121-135	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	103-109	
23749193-3	2013	In this study, we co-administered mice with a nitrile and, to reduce their lethal effects, a selective CYP2E1 inhibitor: diallylsulfide (DAS) or trans-1,2-dichloroethylene (TDCE).	allyl sulfide	137-140	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	103-109	
24373582-8	2014	Notably, ATF4-stimulated ROS production is inhibited in vivo by treatment with diallyl sulphide, a selective CYP2E1 inhibitor.	allyl sulfide	79-95	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	109-115	
22967841-4	2013	Following 2weeks of diet feeding, a cohort of mice started to receive the CYP2E1 inhibitor diallyl sulfide (100mg/kg/d, i.p.)	allyl sulfide	91-106	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	74-80	
23843878-6	2013	And curcumin as well as diallyl sulphide, a CYP2E1 positive inhibitor, ameliorated MPP(+)- and LPS-induced mouse mesencephalic astrocytes damage.	allyl sulfide	24-40	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	44-50	
19875617-5	2009	Compared with the respective control value, the protein levels of CYP2E1 were decreased by 87.40% (p < .01) and 62.26% (p < .01) by 1 day and 60 days of GO treatment, respectively, while the CYP1A2 protein levels were decreased by 70.76% (p < .01) and 41.49% (p < .01), respectively.	allyl sulfide	159-161	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	66-72	
33007364-7	2020	Importantly, VPA-induced ROS accumulation and hepatic steatosis were attenuated when CYP2E1 was inhibited using CYP2E1 inhibitor, diallyl sulfide (DAS, 100 mg/kg in mice, 1 mM in LO2 cells) or in CYP2E1-knockdown cell line, suggesting that CYP2E1 plays a potential role in ROS production following hepatic steatosis.	allyl sulfide	130-145	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	85-91	
16930212-7	2006	RESULTS: The catalase inhibitors sodium azide (5 mM) and aminotriazole (5 mM) as well as CYP2E1 inhibitors diallyl sulfide (2 mM) and beta-phenethyl isothiocyanate (0.1 mM) lowered significantly the accumulation of the ethanol-derived AC and acetate in brain homogenates.	allyl sulfide	107-122	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	89-95	
12060674-9	2002	The knockout animals have increased lipid peroxidation and enhanced sensitivity to CCl4-induced liver damage, which was largely due to increased CYP2E1 expression because diallyl sulfide, an inhibitor of CYP2E1, prevented CCl4-induced liver injury.	allyl sulfide	171-186	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	145-151	
12060674-9	2002	The knockout animals have increased lipid peroxidation and enhanced sensitivity to CCl4-induced liver damage, which was largely due to increased CYP2E1 expression because diallyl sulfide, an inhibitor of CYP2E1, prevented CCl4-induced liver injury.	allyl sulfide	171-186	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	204-210	
10774820-8	2000	The level of CYP2E1 apoprotein in liver microsomes was significantly reduced in the presence of diallyl sulfide.	allyl sulfide	96-111	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	13-19	
16251482-5	2006	Diallyl sulfide (DAS), an inhibitor of CYP2E1, also protected against the cisplatin toxicity in the E47 cells.	allyl sulfide	0-15	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	39-45	
16251482-5	2006	Diallyl sulfide (DAS), an inhibitor of CYP2E1, also protected against the cisplatin toxicity in the E47 cells.	allyl sulfide	17-20	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	39-45	
12784910-7	2003	However, treatment with diallyl sulfide, an inhibitor of cytochrome P450 2E1 mimicked the reduction in O2- production seen in cells overexpressing GH.	allyl sulfide	24-39	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	57-76	
9492391-10	1998	The CYP2E1 inhibitor diallyl sulfide decreased the intensity of immunostaining in the central vein area only.	allyl sulfide	21-36	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	4-10	
34651661-5	2021	Therefore, the present study aimed to investigate whether diallyl sulfide (DAS), a competitive inhibitor of CYP2E1, can be used to inhibit the development of the pathological process of DCM and identify its possible mechanism.	allyl sulfide	58-73	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	108-114	
34651661-5	2021	Therefore, the present study aimed to investigate whether diallyl sulfide (DAS), a competitive inhibitor of CYP2E1, can be used to inhibit the development of the pathological process of DCM and identify its possible mechanism.	allyl sulfide	75-78	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	108-114	
34651661-14	2021	Moreover, the development of DAS analogues with lower cytotoxicity and metabolic rate for CYP2E1 may be beneficial.	allyl sulfide	29-32	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	90-96	
33007364-7	2020	Importantly, VPA-induced ROS accumulation and hepatic steatosis were attenuated when CYP2E1 was inhibited using CYP2E1 inhibitor, diallyl sulfide (DAS, 100 mg/kg in mice, 1 mM in LO2 cells) or in CYP2E1-knockdown cell line, suggesting that CYP2E1 plays a potential role in ROS production following hepatic steatosis.	allyl sulfide	147-150	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	85-91	
33007364-7	2020	Importantly, VPA-induced ROS accumulation and hepatic steatosis were attenuated when CYP2E1 was inhibited using CYP2E1 inhibitor, diallyl sulfide (DAS, 100 mg/kg in mice, 1 mM in LO2 cells) or in CYP2E1-knockdown cell line, suggesting that CYP2E1 plays a potential role in ROS production following hepatic steatosis.	allyl sulfide	147-150	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	112-118	
30463689-3	2019	Adult wild-type (WT) and Akt2-/- mice were treated with the CYP2E1 inhibitor diallyl sulfide (100 mg/kg/d, i.p.)	allyl sulfide	77-92	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	60-66